Topera, Afraxis, Trovagene, & More
Summary
Founded just two years ago, Abide has developed proprietary technology to identify small molecules that block the activity of a superfamily of enzymes known as serine hydrolases, which are associated with a wide range of diseases and disorders.—San Diego-based Topera Medical, which has been developing diagnostic technology and software to pinpoint the origins of electrical impulses that cause abnormal heartbeats, said it has closed on $25 million in a Series C round of financing that was led by New Enterprise Associates, a new investor.But Afraxis restarted last month under the leadership of a new CEO, Carmine Stengone (who led negotiations in the licensing deal with Roche), with Christopher Rex as chief scientific officer.—The U.S. Defense Threat Reduction Agency awarded an $11 million contract to Ichor Medical Systems of San Diego to assess the feasibility and practicality of developing a broad spectrum DNA vaccine for immunizing people against three strains of equine encephalitis virus.—-San Diego’s Ligand Pharmaceuticals (NASDAQ: LGND) said it paid $3.5 million to acquire more than 15 biologic drug development programs from Selexis, the drugmaker based in Geneva, Switzerland.
Classifications
AskAI Classifications
LabelsLinked Companies
